Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marek Filipek

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Folia Medica Cracoviensia|January 7, 2010
Pathophysiology of erectile dysfunction in menKajetan Juszczak, Marek Wyczółkowski, Marek Filipek, et al.
Folia Medica Cracoviensia|December 5, 2008
Animal models of overactive bladder: cyclophosphamide (CYP)-induced cystitis in ratsKajetan Juszczak, Grzegorz Królczyk, Marek Filipek, et al.
Folia Medica Cracoviensia|December 5, 2008
[Percutaneous nephrolithotripsy efficacy assessement in nephrolithiasis treatment]Marek Worek, Marek Filipek, Marek Sandheim, et al.
Lancet (London, England)|December 25, 2007
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialBernard Escudier, Anna Pluzanska, Piotr Koralewski, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Folia Medica Cracoviensia|January 7, 2010
Pathophysiology of erectile dysfunction in menKajetan Juszczak, Marek Wyczółkowski, Marek Filipek, et al.
Folia Medica Cracoviensia|December 5, 2008
Animal models of overactive bladder: cyclophosphamide (CYP)-induced cystitis in ratsKajetan Juszczak, Grzegorz Królczyk, Marek Filipek, et al.
Folia Medica Cracoviensia|December 5, 2008
[Percutaneous nephrolithotripsy efficacy assessement in nephrolithiasis treatment]Marek Worek, Marek Filipek, Marek Sandheim, et al.
Lancet (London, England)|December 25, 2007
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialBernard Escudier, Anna Pluzanska, Piotr Koralewski, et al.
Pageof 1